我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • 哥白尼索引
  • 谷歌学术
  • 打开 J 门
  • Genamics 期刊搜索
  • 宇宙IF
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-世界猫
  • 普布隆斯
  • 日内瓦医学教育与研究基金会
  • 欧洲酒吧
  • ICMJE
分享此页面

抽象的

Controlled-Release Curcumin for the Treatment of Pain Related to Adult Degenerative Scoliosis: A Retrospective, Open-Label, Case-Controlled Series

Morningstar MW*, Megan Strauchman and Gretchen Fleischmann

Background: Patients with adult degenerative scoliosis often experience chronic recurrent back and/or hip pain. This is a very common reason that this patient population seeks treatment. Few treatments are typically offered to adult patients with scoliosis. Of these, the more common are pharmacologic pain management, and epidural injections in more severe cases. The goal of this study was to compare two groups of patients who participated in a scoliosisspecific rehabilitation program. One group additionally took a proprietary curcumin supplement concurrent with therapy. We compared the results of the two groups.

Methods: The results of four consecutive patients with the same diagnosis who took a controlled-release curcumin following a trial of exercise-based scoliosis treatment were collected retrospectively. Outcome assessments included the Cobb angle of the primary curvature, quadruple numerical pain rating scale, and goniometric ranges of motion. Their results were compared against four patients who decided not to take the curcumin formula during their exercise based treatment.

Results: Patients taking the curcumin supplement reported larger average improvements in quadruple numerical pain rating scale taken at baseline and 6 months. Comparative Cobb angles showed similar clinical improvements in the treatment and control groups at 6 months.

Conclusion: Patients taking curcumin daily for 6 months after completing an exercise-based treatment reported statistically significant pain scale improvements compared to baseline and controls. Multiple metabolic and neurologic pathways may account for the observed improvement.